GlassScriptPhysician profile
Kathryn Weston
NPI 1477131647
$9,101.80
in general payments reported to CMS, 2019-2025
24 companies · $5,508 in 2025
The $5,508 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $136 · 2023: $676 · 2024: $2,659 · 2025: $5,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,648 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,648.07 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,721.27 | 2023-2025 | |
| Abbvie INC. | $1,637.54 | 2022-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,220.09 | 2024-2025 | Evenity, Tavneos, Otezla |
| Janssen Biotech, INC. | $862.37 | 2024-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $667.65 | 2024-2025 | Benlysta, Trelegy Ellipta |
| Ucb, INC. | $291.83 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $282.74 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $241.66 | 2025 | Tremfya |
| Mml US, INC. | $131.02 | 2025 | Reactiv8 |
| Kiniksa Pharmaceuticals, LTD. | $130.42 | 2023 | Arcalyst |
| Horizon Therapeutics Plc | $109.65 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $107.86 | 2022-2025 | Cuvitru |
| Lilly USA, LLC | $105.85 | 2024-2025 | Taltz, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $99.19 | 2024-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $76.45 | 2024-2025 | Tyenne, Idacio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.21 | 2023-2025 | Ofev, Spevigo |
| Sobi, INC | $33.73 | 2025 | |
| Novo Nordisk INC | $30.68 | 2025 | Ozempic, Rybelsus |
| Lucid Diagnostics INC. | $19.23 | 2023 | |
| Ani Pharmaceuticals, INC. | $17.90 | 2025 | Sovuna |
| Radius Health, INC. | $17.73 | 2025 | Tymlos |
| Leo Pharma INC. | $17.51 | 2025 | Spevigo |
| Kiniksa Pharmaceuticals International, Plc | $16.71 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.